Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) FCF Margin (2017 - 2025)

Arcus Biosciences has reported FCF Margin over the past 9 years, most recently at 366.67% for Q4 2025.

  • Quarterly results put FCF Margin at 366.67% for Q4 2025, up 2179.0% from a year ago — trailing twelve months through Dec 2025 was 195.95% (down 12773.0% YoY), and the annual figure for FY2025 was 195.95%, down 12773.0%.
  • FCF Margin for Q4 2025 was 366.67% at Arcus Biosciences, up from 373.08% in the prior quarter.
  • Over the last five years, FCF Margin for RCUS hit a ceiling of 3616.67% in Q1 2022 and a floor of 812.2% in Q2 2021.
  • Median FCF Margin over the past 5 years was 246.58% (2022), compared with a mean of 132.96%.
  • Biggest five-year swings in FCF Margin: surged 435609bps in 2022 and later plummeted -402467bps in 2023.
  • Arcus Biosciences' FCF Margin stood at 23.5% in 2021, then tumbled by -839bps to 220.59% in 2022, then tumbled by -243bps to 757.14% in 2023, then soared by 49bps to 388.46% in 2024, then grew by 6bps to 366.67% in 2025.
  • The last three reported values for FCF Margin were 366.67% (Q4 2025), 373.08% (Q3 2025), and 83.12% (Q2 2025) per Business Quant data.